Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 May;23(5):611-4.
doi: 10.1007/s11606-008-0544-x. Epub 2008 Feb 21.

Impact of fixed-dose combination drugs on adherence to prescription medications

Feng Pan  1 , Michael E Chernew, A Mark Fendrick
Affiliations
Comparative Study

Impact of fixed-dose combination drugs on adherence to prescription medications

Feng Pan et al. J Gen Intern Med. 2008 May.

Abstract

Background: The inverse correlation between the complexity of a drug regimen and medication adherence is well established. Fixed-dose combination (FDC) therapies are hypothesized to enhance compliance by decreasing the number of required pills.

Objective: The objective of the study is to compare adherence of a FDC [Glucovance, a FDC of metformin and glyburide] to a 2-pill regimen.

Design: Longitudinal data from a large claims database were used to assess adherence from January 1, 2000, to December 31, 2001. Propensity scoring methods were used to mitigate concerns related to non-random assignment of patients to treatments.

Subjects: The subjects of the study were individuals prescribed metformin or sulfonylurea or both before July 2000, who were prescribed both metformin and sulfonylurea concurrently (either separately or FDC) after August 2000.

Measurements: Adherence was measured by medication possession ratio; the proportion of days on which a patient had medication available.

Results: The FDC enhanced adherence rates by approximately 13% when compared to a 2-pill regimen.

Conclusions: Compared to 2-pill therapy, a FDC resulted in important increases in patient adherence. Economic analyses are warranted to determine whether the clinical benefits attributable to the adherence gains are worth the incremental cost of a FDC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Medication possession ratio by propensity score stratum, before and after the availability of the fixed dose combination product. Legend: The risk stratum denotes the likelihood a patient will switch to the FDC. The line marked by circles illustrates the MPR for patients who switched to the FDC. The line marked by triangles illustrates the MPR for patients who did not switch to the FDC (FDC Fixed dose combination, MPR: medical possession ratio). a MPR by stratum before the FDC was available. b MPR by stratum after the FDC was available.
See this image and copyright information in PMC

References

    1. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a medicaid population. Med Care. 1994;32(3):214–6. - DOI - PubMed
    1. Cantrell C, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44(4):300–3. - DOI - PubMed
    1. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331–42. - DOI - PubMed
    1. Wertheimer AI, Morrison A. Combination drugs: innovation in pharmacotherapy. P&T. 2002;27(1):44–9.
    1. Leichter SB, Thomas S. Combination medications in diabetes care: an opportunity that merits more attention. Clin Diabetes. 2003;21(4):175–8. - DOI

Publication types